1Rushi Deshpande, 2Ashwin Patil, 3Sudhiranjan Dash, 4Shaurya Mehta*
Solid organ transplant recipients are at increased risk of COVID-19. Remdesivir has shown clinical benefit in COVID19. However, there is paucity of data on Remdesivir in solid organ transplant recipients. In this non-randomized interventional study on 12 renal transplant recipients admitted in our institute with COVID 19 infection. Eight patients gave consent for Remdesivir and remaining 4 patients who declined consent for Remdesivir were categorised to control (only standard of care given). Mean hospital stay (10.38 ± 2.62 days) was significantly less in Remdesivir group as compared to mean 18.5 ± 2.08 in control group (p<0.001). Mean duration of oxygen support (in days) was 6.98 ± 2.63 and 12.85 ± 0.91 in the Remdesivir and control groups respectively (p= 0.002) suggesting significantly fewer days of oxygen requirement in Remdesivir group. Magnitude of reduction in CRP was significant (p 0.029) in Remdesivir group. Likewise, LDH reduced significantly in Remdesivir group as compared to controls (p 0.047). There was significant improvement in creatinine (p=0.006) and ferritin (p=0.043) on day 5 in patients who received Remdesivir. No side-effects were observed with Remdesivir. Our small data show that Remdesivir was efficacious and safe in renal transplant recipients with Covid19.
Keywords: COVID-19, Remdesivir, Renal Transplant
English 
Spanish 
Chinese 
German 
French 
Japanese 
Portuguese 
Hindi